Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 5, 2012, Pages 957-965

  Alavi, Maryam ^a   Grebely, Jason ^a   Matthews, Gail V ^a   Petoumenos, Kathy ^a   Yeung, Barbara ^a   Day, Carolyn ^c   Lloyd, Andrew R ^b   van Beek, Ingrid ^d   Kaldor, John M ^a   Hellard, Margaret ^e,n   Dore, Gregory J ^a,m   Haber, Paul ^g   Marks, Pip ^a   Acraman, Brian ^a   Amin, Janaki ^a   Doab, Anna ^a   Carroll, Therese ^a   Ffrench, Rose ^e   Flynn, Jacqueline ^e   Goy, Kylie ^e   Nguyen, Oanh ^e   von Bibra, Sally ^e   White, Peter ^b   Li, Hui ^b   Oon, Alieen ^b   Cameron, Barbara ^b   Rawlinson, William ^f   Dolan, Kate ^b   Jacka, Brendan ^f   Pan, Yong ^f   McCaughan, Geoff ^g   Madden, Annie ^h   Farrell, Geoff ⁱ   Crofts, Nick ^j   Sievert, William ^k   Baker, David ^l   Desmond, Paul ^m   Shaw, David ^o   Sasadeusz, Joe ^p   Crawford, Darrell ^q   Phung, Nghi ^r   George, Jacob ^s   Bloch, Mark ^t   Hughes, Brian ^u   Mollison, Lindsay ^v   Roberts, Stuart ⁿ   more..

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Kirketon Road Centre   (Australia)

^e BURNET INSTITUTE   (Australia)

^f SEALS   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h Australian Injecting and Illicit Drug Users League   (Australia)

ⁱ CANBERRA HOSPITAL   (Australia)

^j Nossal Institute   (Australia)

^k MONASH MEDICAL CENTRE   (Australia)

^l 407 Doctors   (Australia)

^m ST VINCENT S HOSPITAL   (Australia)

ⁿ ALFRED HOSPITAL   (Australia)

^o ROYAL ADELAIDE HOSPITAL   (Australia)

^p ROYAL MELBOURNE HOSPITAL   (Australia)

^q PRINCESS ALEXANDRA HOSPITAL   (Australia)

^r NEPEAN HOSPITAL   (Australia)

^s WESTMEAD HOSPITAL   (Australia)

^t John Hunter Hospital ^*  (Australia)

^u JOHN HUNTER HOSPITAL   (Australia)

^v FREMANTLE HOSPITAL   (Australia)

more..

Author keywords

Anxiety; Depression; Hepatitis C virus; Injecting drug users; Psychiatric

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY DISORDER; ARTICLE; DEPRESSION; DEPRESSION ANXIETY AND STRESS SCALE; DRUG EFFECT; EMPLOYMENT; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOLOGIC TEST; SOCIAL STATUS; TREATMENT DURATION;

EID: 84860233144     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07035.x     Document Type: Article

References (38)

1. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-82.
2. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
3. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
4. Schaefer M, Engelbrecht MA, Gut O etal. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. [Review][125 refs]. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002; 26: 731-46.
5. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44: 104-12.
6. Hauser P, Khosla J, Aurora H etal. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol. Psychiatry 2002; 7: 942-7.
7. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J. Clin. Psychiatry 2003; 64: 708-14.
8. Schaefer M, Hinzpeter A, Mohmand A etal. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991-8.
9. Schäfer A, Wittchen H-U, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int. J. Methods Psychiatr. Res. 2007; 16: 186-201.
10. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. (Erratum appears in Arch Gen Psychiatry. 2005 Jul;62(7):768 Note: Merikangas, Kathleen R [added]). Arch. Gen. Psychiatry 2005; 62: 593-602.
11. El-Serag HB, Kunik M, Richardson P, Rabeneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-82.
12. Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41: 377-84.
13. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. [Review][143 refs]. Lancet Infect. Dis. 2005; 5: 558-67.
14. Topp L, Hudson SL, Maher L. Mental health symptoms among street-based psychostimulant injectors in Sydney's Kings Cross. Subst. Use Misuse 2010; 45: 1180-200.
15. Darke S, Kaye S. Attempted suicide among injecting and noninjecting cocaine users in Sydney, Australia. J. Urban Health 2004; 81: 505-15.
16. Darke S, Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug Alcohol Depend. 1997; 48: 135-41.
17. Grebely J, Petoumenos K, Matthews GV etal. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: the ATAHC Study. Drug Alcohol Depend. 2010; 107: 244-9.
18. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 2009; 49: 561-73.
19. Dore GJ, Hellard M, Matthews GV etal. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138: 123-35.
20. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br. J. Addict. 1992; 87: 733-42.
21. Sheehan DV, Lecrubier Y, Sheehan KH etal. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. [Review][25 refs]. J. Clin. Psychiatry 1998; 20: 22-33.
22. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br. J. Clin. Psychol. 2005; 44: 227-39.
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV-TR axis I disorders. Research version. Biometrics Research, New York State Psychiatric Institute, New York/Non-patient edition, (SCID-I/NP). 2001.
24. Robins LN, Wing J, Wittchen HU etal. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch. Gen. Psychiatry 1989; 45: 1069-77.
25. Grebely J, Matthews GV, Hellard M etal. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J. Hepatol. 2011; 55: 76-85.
26. Bini EJ, Brau N, Currie S etal. Prospective multicenter study of eligibility for antiviral therapy among 4084 U.S. veterans with chronic hepatitis C virus infection. Am. J. Gastroenterol. 2005; 100: 1772-9.
27. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.
28. Evon DM, Simpson KM, Esserman D, Verma A, Smith S, Fried MW. Barriers to accessing care in patients with chronic hepatitis C: the impact of depression. Aliment. Pharmacol. Ther. 2010; 32: 1163-73.
29. Gidding HF, Law M, Amin J etal. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med. J. Aust. 2011; 194: 398-402.
30. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr. Serv. 2006; 57: 570-2.
31. Marcellin F, Preau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin. Trials 2007; 8: 320-7.
32. Dalgard O, Egeland A, Skaug K, Vilimas K, Steen T. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004; 39: 74-80.
33. Dietze P, Stoove M, Miller P etal. The self-reported personal wellbeing of a sample of Australian injecting drug users. Addiction 2010; 105: 2141-8.
34. Schmidt F, Janssen G, Martin G etal. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment. Pharmacol. Ther. 2009; 30: 1049-59.
35. Schaefer M, Schmidt F, Folwaczny C etal. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
36. Evon DM, Ramcharran D, Belle SH etal. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am. J. Gastroenterol. 2009; 104: 2949-58.
37. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J. Affect. Disord. 2004; 82: 175-90.
38. Maes M, Yirmyia R, Noraberg J etal. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009; 24: 27-53.